Related references
Note: Only part of the references are listed.Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial
Hyun-Ah Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Overcoming Endocrine Resistance in Breast Cancer
Ariella B. Hanker et al.
CANCER CELL (2020)
CYP27A1 expression is associated with risk of late lethal estrogen receptor-positive breast cancer in postmenopausal patients
Siker Kimbung et al.
BREAST CANCER RESEARCH (2020)
Intratumoral Sterol-27-Hydroxylase (CYP27A1) Expression in Relation to Cholesterol Synthesis and Vitamin D Signaling and Its Association with Lethal Prostate Cancer
Nabeela A. Khan et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2019)
Host CYP27A1 expression is essential for ovarian cancer progression
Sisi He et al.
ENDOCRINE-RELATED CANCER (2019)
Cholesterol and 27-hydroxycholesterol promote thyroid carcinoma aggressiveness
Giovanna Revilla et al.
SCIENTIFIC REPORTS (2019)
Breast cancer
Nadia Harbeck et al.
NATURE REVIEWS DISEASE PRIMERS (2019)
Statin use and breast cancer survival - a Swedish nationwide study
Signe Borgquist et al.
BMC CANCER (2019)
The significance of cholesterol and its metabolite, 27-hydroxycholesterol in breast cancer
Erik R. Nelson
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2018)
Impact of 27-hydroxylase (CYP27A1) and 27-hydroxycholesterol in breast cancer
Siker Kimbung et al.
ENDOCRINE-RELATED CANCER (2017)
Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study
Signe Borgquist et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
The cholesterol metabolite 27 hydroxycholesterol facilitates breast cancer metastasis through its actions on immune cells
Amy E. Baek et al.
NATURE COMMUNICATIONS (2017)
CYP27A1 Loss Dysregulates Cholesterol Homeostasis in Prostate Cancer
Mahmoud A. Alfaqih et al.
CANCER RESEARCH (2017)
Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
Prudence A. Francis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
Olivia Pagani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Statin Use and Breast Cancer Survival: A Nationwide Cohort Study from Finland
Teemu J. Murtola et al.
PLOS ONE (2014)
Cholesterol and breast cancer pathophysiology
Erik R. Nelson et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2014)
A prospective, multicenter validation study of a prognostic index composed of S-phase fraction, progesterone receptor status, and tumour size predicts survival in node-negative breast cancer patients: NNBC, the node-negative breast cancer trial
M. Klintman et al.
ANNALS OF ONCOLOGY (2013)
27-Hydroxycholesterol Links Hypercholesterolemia and Breast Cancer Pathophysiology
Erik R. Nelson et al.
SCIENCE (2013)
27-Hydroxycholesterol Promotes Cell-Autonomous, ER-Positive Breast Cancer Growth
Qian Wu et al.
CELL REPORTS (2013)
Liver x receptor ligands disrupt breast cancer cell proliferation through an E2F-mediated mechanism
Trang Nguyen-Vu et al.
BREAST CANCER RESEARCH (2013)
A comprehensive method for extraction and quantitative analysis of sterols and secosteroids from human plasma
Jeffrey G. McDonald et al.
JOURNAL OF LIPID RESEARCH (2012)
RNAscope A Novel in Situ RNA Analysis Platform for Formalin-Fixed, Paraffin-Embedded Tissues
Fay Wang et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2012)
Statin Prescriptions and Breast Cancer Recurrence Risk: A Danish Nationwide Prospective Cohort Study
Thomas P. Ahern et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
The oxysterol receptor LXR inhibits proliferation of human breast cancer cells
Lise-Lotte Vedin et al.
CARCINOGENESIS (2009)
Long-term outcomes of aromatase inhibition for breast cancer
Masakazu Toi
LANCET ONCOLOGY (2008)
27-hydroxycholesterol is an endogenous selective estrogen receptor modulator
Carolyn D. DuSell et al.
MOLECULAR ENDOCRINOLOGY (2008)
27-hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen
Michihisa Umetani et al.
NATURE MEDICINE (2007)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
REporting recommendations for tumour MARKer prognostic studies (REMARK)
LM McShane et al.
BRITISH JOURNAL OF CANCER (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
LXRs; Oxysterol-activated nuclear receptors that regulate genes controlling lipid homeostasis
PA Edwards et al.
VASCULAR PHARMACOLOGY (2002)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Drug therapy - Side effects of adjuvant treatment of breast cancer
CL Shapiro et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer
P Malmström et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
